BCRX fundamentals
An in-depth look to BioCryst Pharmaceuticals, Inc. operating, investing, and financing activities
BCRX free cash flow for Q4 23 is -9.47 M USD. For 2023, BCRX free cash flow was -97.31 M USD and operating cash flow was -95.14 M USD.
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
TTM